Clinical study on Qianggu Shengxue Oral Liquid combined with calcitriol in treatment of postmenopausal osteoporosis
Objective To investigate the clinical efficacy of Qianggu Shengxue Oral Liquid combined with calcitriol in treatment of postmenopausal osteoporosis.Methods Patients(124 cases)with postmenopausal osteoporosis in Wuhan Hospital of Traditional Chinese Medicine from June 2022 to June 2023 were randomly divided into control(62 cases)and treatment(62 cases)group.Patients in the control group were po administered with Calcitriol Soft Capsules,0.25 µg/time,twice daily.Patients in the treatment group were po administered with Qianggu Shengxue Oral Liquid on the basis of the control group,30 mL/time,three times daily.Patients in two groups were treated for 12 weeks.After treatment,the clinical evaluations was evaluated,the time of symptom relief,the levels of bone metabolic markers BGP,BALP,OPG and N-MID,the serological IL-6,TNF-α,CRP and ICF-1 levels in two groups before and after treatment were compared.Results After treatment,the clinical effective rate in the treatment group was 98.39% ,which was significantly higher than that of the control group(83.87% ,P<0.05).After treatment,the time of symptom improvement in the treatment group was significantly shorter than that in the control group(P<0.05).After treatment,the levels of BGP,BALP,OPG and ICF-1 were significantly increased,while the levels of N-MID,IL-6,TNF-α and CRP were significantly decreased in two groups,and these indexes in the treatment group were significantly better than those in the control group(P<0.05).Conclusion Qianggu Shengxue Oral Liquid combined with calcitriol in treatment of postmenopausal osteoporosis has a definite therapeutic effect,which can significantly relieve clinical symptoms,effectively improve bone metabolism,and promote the weakening of inflammatory reaction.
NETL
NSTL
万方数据
维普
